Proteomics Market

Proteomics Market Outlook (2022 to 2032)

The global Proteomics market size reached a valuation of USD 30,825.04 Million in 2022. Increasing adoption of precision medicine and sophisticated diagnostics in specific target disease treatment, as well as the increased concentration of target diseases, are significant drivers of growth prospects.

Demand for Proteomics is projected to grow at a robust CAGR of 13.5% between 2022 and 2032, totaling around USD 109,485.7 Million by the end of 2032.

Data Points	Key Statistics
Proteomics Market Size (2022)	USD 30,825.04 Million
Proteomics Market Revenue Forecast (2032)	USD 109,485.7 Million
Proteomics Market Growth Rate (2022 to 2032)	13.5% CAGR
North America Market Share	35%

A proteome is the complete set of proteins produced by a system or organism. It can transform based on the time, specifications, and stresses that an organism is confined to. Proteomic research refers to the systematic study of proteins on a large scale. Because proteins are the fundamental units of cells, proteomic research aims to answer all questionnaires about them.

Breakthroughs in mass spectrometry and protein and DNA sequence databases can assist proteomics research. Proteomics necessitates a wide range of instruments, machinery, reagents, media, and software for protein identification, quantitative determination, and recognition of protein interactions.

Which Factors Are Driving The Growth Of The Proteomics Market?

Continued growth for personalized medicine, technical progress, and innovation, as well as enhanced funding opportunities from both the public and private sectors for proteomics, are among the most crucial driving factors in the proteomics industry.

Because the pharmaceutical and biopharmaceutical markets are expanding rapidly, the clamor for proteomics has accelerated. Furthermore, the global industry is anticipated to expand rapidly in the coming decades as an outcome of technological advancements, extensive research funding, escalating healthcare costs, rising numbers for tailored medication, and price inflation of genetic illnesses.

Another factor expected to propel overall growth is the higher incidence of chronic diseases such as cancer, Cardiovascular Diseases (CVDs), respiratory diseases, CKD, and others. As per Globocan, there were 19.3 million new cancer patients and 10 million cancer-related deaths globally in December 2020. Similarly, CVDs are among the world's most prevalent causes of death.

Which Factors Are Restraining The Growth Of The Proteomics Market?

Despite its numerous benefits and wonderful features, proteomics also has a few drawbacks. The high price of medicines and equipment, as well as a scarcity of research scholars, are stifling the proteomics market.

How Will Growth Unfold In The North America Proteomics Market?

North America dominated the market in 2021, with a 46% revenue share. This is due to higher investments in the innovation of structure-based drug design, advancement in omics research, the requirement for high-quality research tools for data replicability, and a focus on the creation of tailored treatments.

Agreements and collaborations among major corporations in this region are also assisting in the advancement of this market.

For example, Thermo Fisher Scientific Inc. and Symphogen collaborated to create validated platform mechanisms for the streamlined classification and monitoring, and management of complex protein therapeutics. North America is accounting for a market share of 35% of the global Proteomics market.

Which Factors Are Pushing The Proteomics Demand In The Asia Pacific?

Rapid growth for personalized medicines, as well as increased research and development in proteomics, are acting as a catalyst in the market. The clamor for spectroscopy proteomics is likely to increase as the prevalence of breast cancer rises. This is expected to aid the advancement of the Asia-Pacific proteomics market.

These are the primary drivers that will continue to fuel the biopharmaceutical firm's endeavor of blockbuster drugs, as well as the latest technological advancements in gene and protein research.

Because it is challenging for organizations to find all of the required expertise to encompass all of the activities associated with proteomics, alliances seem to become progressively crucial in this field. Many manufacturers, for example, are cooperating with mass spectrometry, and both automakers and end-user labs are partnering with protein chip-related companies.

How Will Growth Unfold In The European Proteomics Market?

The global market for personalized medicine in Europe, as well as the existence of major market players such as Merck KGaA, are expected to propel growth in the region. Additionally, proactive support from European local governments and approaches by research organizations to develop proteomics technologies such as chemo proteomics and spectrometry is expected to fuel market growth.

Rising research grants and active projects by European research institutes and big players, especially in the United Kingdom, drive demand in the researched market.

For example, in December 2020, the United Kingdom Biobank collaborated on the Pharma Proteomics Project with the Biopharma Consortium, which included ten biopharmaceutical enterprises. Europe is accounting for a market share of 23.1% of the global proteomics market.

Category-Wise Analysis

Which Segments Dominate the Global Proteomics Market?

In 2021, the spectroscopy segment had the largest share of revenue at more than 46.9%. During the projected timeline, it is presumed to accelerate at the fastest rate. The pervasive use of spectroscopy-based technological innovations in many application domains, such as drug development procedures, proteomics, metabolomics, forensic investigation, and pharmacological analysis, is one of the major drivers of segment growth.

In 2021, the clinical diagnostics segment led the industry with a market share of more than 52%. This is due to the extensive use of protein analysis by clinical researchers to identify disease biomarkers for early recognition and specific risk factors.

This is anticipated to open up new avenues for ailment early detection and prevention. It is possible to discover potential biomarkers and nutrient expression patterns that can be utilized to classify and anticipate tumors, as well as ascertain their prognosis, using proteomics-based medical assessment, which contributes significantly to the segment's development.

The Start-up Ecosystem

How key Players are opening Frontiers for Future Growth?

Manufacturers are adopting various marketing strategies such as new product launches, geographical expansion, mergers and acquisitions, partnerships, and collaboration to identify the interest of potential buyers and create a larger customer base.

For instance,

• Fastbase Solutions was established in 2015. Fastbase Solutions, a development company of proteomic technology, and Lambert Instruments BV, a creator of imaging solutions, recently announced a strategic agreement to launch a new cancer diagnostics platform.
• Evosep was established in 2016. SCIEX and Evosep declared a partnership deal in November 2022 to co-market products designed to enhance robust, high-throughput proteomics workflows for personalized medicine.

Who are the Leading Players in Proteomics Market?

Some of the leading Proteomics manufacturers include Agilent Technologies, Thermo Fisher Scientific Inc., Danaher Corporation, Genzyme Corporation, GE Healthcare, Bio-Rad Laboratories, Inc., Affymetrix Inc, Seer, SCIEX, and SomaLogic.

These key proteomics providers are adopting various strategies such as new product launches and approvals, partnerships, collaborations, acquisitions, mergers, etc. to increase their sales and gain a competitive edge in the global proteomics market.

For instance

• Seer Corporation announced the broad commercial release of the Proteograph Product Suite and the Centers of Excellence program in January 2022.
• The clinical trial to assess the diagnosis of disseminated Lyme borreliosis by focused proteomics began in February 2021 at University Hospital in Strasbourg, France.
• SCIEX (Danaher Corporation) released the next-generation mass spectrometer, the SCIEX Triple Quad 7500 LC-MS/MS System - QTRAP Ready, in July 2020.
• SomaLogic raised an additional USD 80 million in investment as part of its Series A financing round in December 2020. The influx of fundraising in the field of proteomics is expected to accelerate the proteomics market over the coming years.

Report Scope

Report Attribute	Details
Growth Rate	CAGR of 13.5% from 2022 to 2032
Market Value in 2022	USD 30,825.04 Million
Market Value in 2032	USD 109,485.7 Million
Base Year for Estimates	2021
Historical Data	2016 to 2021
Forecast Period	2022 to 2032
Quantitative Units	Revenue in USD Million and CAGR from 2022 to 2032
Report Coverage	Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered	Service, Application, Equipment, Region
Regions Covered	North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East and Africa
Key Countries Profiled	USA, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, China, Japan, South Korea, Singapore, Thailand, Indonesia, Australia, New Zealand, GCC Countries, South Africa, Israel
Key Companies Profiled	Agilent Technologies, Thermo Fisher Scientific Inc., Danaher Corporation, Genzyme Corporation, GE Healthcare, Bio-Rad Laboratories, Inc., Affymetrix Inc., Seer, SCIEX, SomaLogic.
Report Customization & Pricing	Available upon Request

Proteomics Market: Segmentation

By Equipment:

• Chromatography
• Mass Spectroscopy
• Protein Microarray
• X-ray Crystallography
• Protein fractionation
• Others

By Services:

• Laboratory Service
• Data Analysis and Services

By Application:

• Drug Discovery
• Clinical Diagnosis
• Others

Frequently Asked Questions

What is the current valuation of Proteomics market?

The global Proteomics market reached US$ 30825.04 Million in 2022.

What is the anticipated growth rate for Proteomics during the projected period?

As per FMI, the Proteomics industry is expected to grow at a CAGR of 13.5% throughout the forecast period (2022 to 2032).

What is the projected valuation for Proteomics market by 2032?

The global sales of Proteomics are anticipated to total a valuation of US$ 109485.7 Million by 2032.

Who are the prominent Proteomics providers?

Some of the leading manufacturers include Agilent Technologies, Thermo Fisher Scientific Inc., Danaher Corporation, Genzyme Corporation, GE Healthcare, Bio-Rad Laboratories, Inc., Affymetrix Inc, Seer, SCIEX, and SomaLogic.

Which is the leading market for Proteomics?

North America will continue to remain the most lucrative market for proteomics, accounting for a share of 35% of the global Proteomics market in 2022.